Sector: Biotech / Healthcare
Platform: Wefunder
Minimum investment: $250
What They Do
Siren is developing a universal immuno-gene therapy platform that combines AAV (adeno-associated virus) delivery with immune system engineering. Their mission: build scalable, off-the-shelf treatments for aggressive cancers that work better and faster than current options.
Why It Might Be the Next Big Thing
Immunotherapy and gene therapy are two of the most powerful tools in cancer treatment. Siren is fusing them into a single, more adaptable platform. If they succeed, they won’t just treat one cancer—they could unlock a whole new class of treatments for many.
Snapshot
Universal gene-immunotherapy platform
Scalable, off-the-shelf design
Tackling tough-to-treat cancers
My Take
This is serious science with massive potential. It’s high risk, but if they can get traction in trials, the upside—both medical and financial—could be enormous.